

(51) International Patent Classification:
C07D 471/10 (2006.01) A61K 31/4747 (2006.01)(21) International Application Number:
PCT/US2023/060787(22) International Filing Date:
17 January 2023 (17.01.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/300,592 18 January 2022 (18.01.2022) US
63/311,668 18 February 2022 (18.02.2022) US
63/332,553 19 April 2022 (19.04.2022) US
63/400,359 23 August 2022 (23.08.2022) US
63/422,341 03 November 2022 (03.11.2022) US(71) Applicant: MAZE THERAPEUTICS, INC. [US/US];
171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(72) Inventors: LEE, Patrick Sang Tae; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). EWING, Todd Jonathan August; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). REID, Adam Neil; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). SINZ, Christopher Joseph; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). ZHANG, Birong; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). BRONNER, Sarah M.; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). MORGANS, David John; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). HOEK, Maarten; c/o


o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). ASSIMON, Victoria Anne; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). ZIEBENHAUS, Chris; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). SCHAMMEL, Alexander Wayne; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(74) Agent: MCBRIAR, Mark D. et al.; 200 Clarendon Street, 21st Floor, Boston, Massachusetts 02116 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: APOL1 INHIBITORS AND METHODS OF USE

(57) Abstract: Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m , n , p , R^1 , R^2 , R^3 , L^1 , L^2 , L^3 , R^4 , X^1 , X^2 , X^3 , and X^4 are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition in an individual.

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*